The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...

Fred Hutch and MSK researchers showed that tumors driven by hiccups in RNA processing can't hid from the immune system. In ...

Prime Medicine, Inc.’s PRME share price has dipped by 5.43%, which has investors questioning if this is right time to buy.

An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a ...

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage ...

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients with myelodysplastic ...

Since sharing their story online, support has poured in from across the country. Over €147,000 has been raised via GoFundMe, ...

ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...